Clinical Trial Update: Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 [Phase 3]

View source ↗

Summary

Phase 3 trial comparing standard-dose versus intermediate-dose cytarabine induction in acute myeloid leukemia with RUNX1-RUNX1T1 fusion; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML, RUNX1-RUNX1T1 Fusion Protein Expression | Phase 3 | Status: RECRUITING